| Literature DB >> 35796405 |
Linda Campos-Fernández1,2,3, Rocío Ortiz-Muñiz2, Edith Cortés-Barberena2, Sergio Mares-Sámano4, Ramón Garduño-Juárez5, Catalina Soriano-Correa3.
Abstract
Chagas disease is caused by Trypanosoma cruzi. Benznidazole and nifurtimox are drugs used for its therapy; nevertheless, they have collateral effects. NADH-fumarate (FUM) reductase is a potential pharmacological target since it is essential for survival of parasite and is not found in humans. The objectives are to design and characterize the electronic structure of imidazole and nitroimidazole derivatives at DFT-M06-2X level in aqueous solution; also, to model the NADH-FUM reductase and analyze its intermolecular interactions by molecular docking. Quantum-chemical descriptors allowed to select the molecules with the best physicochemical properties and lowest toxicity. A high-quality three-dimensional structure of NADH-FUM reductase was obtained by homology modeling. Water molecules do not have influence in the interaction between FUM and NADH-FUM reductase. The main hydrogen-binding interactions for FUM were identified in NADH, Lys172, and Arg89; while hydrophobic interactions in Phe479, Thr174, Met63. The molecules S3-8, S2-8, and S1-8 could be inhibitors of NADH-FUM reductase.Entities:
Keywords: Chagas disease; DFT calculations; NADH-fumarate reductase; homology modeling; molecular docking
Mesh:
Substances:
Year: 2022 PMID: 35796405 PMCID: PMC9541967 DOI: 10.1002/jcc.26959
Source DB: PubMed Journal: J Comput Chem ISSN: 0192-8651 Impact factor: 3.672
FIGURE 1Head structures of series ,
FIGURE 2Selected structures of the 2‐nitroimidazole and 5‐nitroimidazole derivatives, according to their pharmacokinetic parameters and toxicological predictions results. For SESE calculations: X is a transmitting moiety (imidazole ring linked to R1 or R2 groups, respectively) and the R9 is the substituent group
FIGURE 3Selected structures of the imidazole derivatives according to their pharmacokinetic parameters and toxicological predictions results
FIGURE 4Optimized structures for 2‐nitroimidazole and 5‐nitroimidazole derivatives at the M06‐2X/6‐311+G(d,p) levels of theory. The H, C, N, S, and O atoms are represented as white, gray, blue, yellow, and red balls, respectively
FIGURE 5Optimized structures for imidazole derivatives at the M06‐2X/6‐311+G(d,p) levels of theory. The H, C, N, S, and O atoms are represented as white, gray, blue, yellow, and red balls, respectively
Proton affinity and quantum‐chemical descriptors for reference and selected molecules, at the M06‐2X/6‐311++G(2df,2p)//6‐311+G(d,p) levels of theory
| Molecule | PA (kcal/mol) |
|
|
| SESE (kcal/mol) | ∆ (eV) | |
|---|---|---|---|---|---|---|---|
| Ref. Mol. | BNZ | 15.37 | 10.18 | 6.83 | 0.15 | −0.47 | 0.24 |
| M3 | 8.21 | 10.09 | 6.88 | 0.17 | 10.23 | 0.18 | |
| M35m | 14.67 | 10.18 | 6.88 | 0.16 | −0.70 | 0.08 | |
| M2 | 12.92 | 10.01 | 6.82 | 0.16 | 0.42 | 0.16 | |
| M7D | 8.92 | 10.46 | 7.20 | 0.19 | 7.66 | 0.20 | |
| Imidazoles | S1‐1 | −0.15 | 7.36 | 6.47 | 0.53 | – | 0.31 |
| S1‐6 | 0.24 | 7.69 | 6.54 | 0.47 | – | 0.07 | |
| S1‐8 | 0.05 | 8.39 | 6.45 | 0.30 | – | 0.21 | |
| S2‐1 | −2.36 | 7.18 | 6.22 | 0.48 | – | 0.68 | |
| S2‐6 | −2.40 | 7.39 | 6.24 | 0.44 | – | 0.15 | |
| S2‐8 | −2.29 | 8.16 | 6.22 | 0.28 | – | 0.08 | |
| S3‐1 | −1.91 | 7.15 | 6.19 | 0.48 | – | 0.71 | |
| S3‐6 | −0.58 | 7.39 | 6.21 | 0.43 | – | 0.21 | |
| S3‐8 | −1.30 | 8.12 | 6.19 | 0.28 | – | 0.10 | |
| S4‐1 | 1.80 | 6.96 | 6.02 | 0.46 | – | 1.01 | |
| S4‐8 | 1.80 | 7.95 | 6.02 | 0.26 | – | 0.30 | |
| Nitroimidazoles | 2NS5‐2 | 16.86 | 10.78 | 7.38 | 0.18 | −2.02 | 0.08 |
| 2NS1‐6 | 16.60 | 9.89 | 6.55 | 0.13 | 2.40 | 0.11 | |
| 2NS5‐3 | 16.69 | 10.40 | 7.02 | 0.16 | −2.03 | 0.32 | |
| 2NS3‐6 | 16.11 | 9.85 | 6.54 | 0.13 | 0.88 | 0.11 | |
| 2NS3‐7 | 14.94 | 10.51 | 7.22 | 0.18 | −1.44 | 0.15 | |
| 5NS2‐6 | 8.47 | 9.75 | 6.53 | 0.14 | 10.44 | 0.07 | |
| 5NS1‐1 | 11.17 | 10.17 | 6.91 | 0.16 | 11.20 | 0.16 | |
| 5NS5‐4 | 14.18 | 10.23 | 6.97 | 0.17 | −0.27 | 0.25 |
Abbreviations: eV, electron Volts; I, ionization potential; PA, proton affinity energy; SESE, substituent effect stabilization energy; Δ, aromatic index; η, chemical hardness; ω, electrophilicity index.
Values obtained from Reference [16].
Values obtained from Reference [15].
Atomic charges values for imidazole and nitroimidazole derivatives at the M06‐2X/6‐311++G(2df,2p)//6‐311+G(d,p) levels
| Molecule | N1 | C2 | N3 | C4 | C5 | O7 | O8 | R9 | NO2 |
|---|---|---|---|---|---|---|---|---|---|
| BNZ | 0.314 | 0.201 | −0.595 | 0.221 | −0.347 | −0.511 | −0.528 | 0.071 | −0.212 |
| M3 | 0.257 | 0.444 | −0.683 | 0.269 | −0.357 | −0.558 | −0.564 | 0.050 | −0.169 |
| M35m | −0.228 | 0.432 | −0.604 | 0.059 | 0.143 | −0.489 | −0.453 | 0.308 | −0.309 |
| M2 | 0.075 | 0.706 | −0.649 | 0.207 | −0.316 | −0.569 | −0.581 | 0.100 | −0.191 |
| M7D | −0.021 | 0.545 | −0.683 | 0.244 | −0.243 | −0.547 | −0.556 | 0.167 | −0.183 |
| S1‐1 | 0.291 | 0.167 | −0.685 | 0.220 | −0.471 | – | – | 0.028 | – |
| S1‐6 | 0.300 | 0.147 | −0.680 | 0.199 | −0.419 | – | – | 0.030 | – |
| S1‐8 | 0.172 | 0.211 | −0.694 | 0.212 | −0.388 | – | – | 0.098 | – |
| S2‐1 | −0.039 | 0.525 | −0.738 | 0.171 | −0.395 | – | – | 0.200 | – |
| S2‐6 | 0.229 | 0.408 | −0.727 | 0.152 | −0.449 | – | – | 0.047 | – |
| S2‐8 | 0.121 | 0.446 | −0.732 | 0.152 | −0.398 | – | – | 0.105 | – |
| S3‐1 | −0.074 | 0.235 | −0.689 | 0.060 | 0.060 | – | – | 0.182 | – |
| S3‐6 | 0.250 | 0.135 | −0.678 | 0.073 | −0.106 | – | – | −0.002 | – |
| S3‐8 | 0.082 | 0.189 | −0.677 | 0.046 | 0.002 | – | – | 0.101 | – |
| S4‐1 | 0.027 | 0.682 | −0.677 | 0.052 | −0.378 | – | – | 0.116 | – |
| S4‐8 | −0.068 | 0.743 | −0.695 | 0.075 | −0.365 | – | – | 0.172 | – |
| S5‐1 | 0.129 | 0.454 | −0.724 | 0.191 | −0.402 | – | – | 0.058 | – |
| 2NS5‐2 | 0.280 | 0.242 | −0.575 | 0.201 | −0.273 | −0.459 | −0.419 | 0.062 | −0.244 |
| 2NS1‐6 | 0.367 | 0.178 | −0.585 | 0.222 | −0.355 | −0.486 | −0.477 | 0.022 | −0.194 |
| 2NS5‐3 | 0.026 | 0.339 | −0.579 | 0.078 | 0.059 | −0.467 | −0.426 | 0.132 | −0.279 |
| 2NS3‐6 | 0.226 | 0.177 | −0.567 | 0.080 | −0.002 | −0.504 | −0.483 | 0.059 | −0.205 |
| 2NS3‐7 | 0.158 | 0.183 | −0.560 | 0.062 | 0.030 | −0.525 | −0.531 | 0.122 | −0.230 |
| 5NS2‐6 | 0.167 | 0.461 | −0.681 | 0.236 | −0.271 | −0.487 | −0.546 | 0.068 | −0.186 |
| 5NS1‐1 | 0.378 | 0.228 | −0.630 | 0.259 | −0.328 | −0.540 | −0.509 | −0.023 | −0.148 |
| 5NS5‐4 | −0.045 | 0.778 | −0.683 | 0.209 | −0.209 | −0.524 | −0.453 | 0.177 | −0.236 |
Note: Atomic charges of atoms and groups are in a.u.
Values obtained from Reference [16].
Values obtained from Reference [15]
Condensed Fukui function values for imidazole and nitroimidazole derivatives at the M06‐2X/6‐311++G(2df,2p)//6‐311+G(d,p) levels
| Mol |
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C2 | N3 | C4 | C5 | R9 | N6 | O7 | O8 | R9 | C4 | C5 | O7 | O8 | |
| BNZ | – | – | – | – |
0.145 C21 0.181 C29 | 0.164 | 0.245 | 0.212 | – | 0.027 | 0.034 | 0.123 | 0.106 |
| M3 | – | – | – | – |
0.148 C16 0.181 C24 | 0.159 | 0.229 | 0.192 | – | 0.051 | 0.013 | 0.115 | 0.097 |
| M35m | 0.132 | 0.065 | 0.188 | 0.145 | – | 0.163 | 0.239 | 0.196 | – | 0.121 | 0.099 | 0.158 | 0.129 |
| M2 | 0.078 | 0.087 | 0.115 | 0.141 | – | 0.156 | 0.223 | 0.191 | – | 0.113 | 0.085 | 0.159 | 0.129 |
| M7D | 0.109 | 0.085 | 0.135 | 0.162 | – | 0.160 | 0.230 | 0.198 | – | 0.118 | 0.094 | 0.164 | 0.133 |
| S1‐1 | 0.161 | 0.090 | 0.202 | 0.216 | – | – | – | – |
0.153 C20 0.152 C24 | 0.102 | 0.108 | – | – |
| S1‐6 | – | – | – | – |
0.123 C22 0.136 C24 | – | – | – |
0.129 C20 0.133 C24 | – | – | – | – |
| S1‐8 | – | – | – | – |
0.142 N32 0.167 N33 | – | – | – |
0.109 C21 0.108 C25 | – | – | – | – |
| S2‐1 | 0.123 | 0.087 | 0.197 | 0.208 | – | – | – | – |
0.141 C19 0.145 C23 | 0.099 | 0.105 | – | – |
| S2‐6 | 0.122 | 0.088 | 0.196 | 0.210 | – | – | – | – |
0.129 C19 0.133 C23 | 0.099 | 0.105 | – | – |
| S2‐8 | 0.123 | 0.088 | 0.197 | 0.210 | – | – | – | – |
0.109 C20 0.108 C24 | 0.099 | 0.105 | – | – |
| S3‐1 | 0.158 | 0.089 | 0.199 | 0.167 | – | – | – | – |
0.142 C20 0.145 C21 | 0.101 | 0.084 | – | – |
| S3‐6 | 0.160 | 0.089 | 0.199 | 0.168 | – | – | – | – |
0.123 C19 0.131 C23 | 0.100 | 0.084 | – | – |
| S3‐8 | 0.158 | 0.089 | 0.199 | 0.167 | – | – | – | – |
0.109 C20 0.108 C24 | 0.100 | 0.084 | – | – |
| S4‐1 | 0.094 | 0.091 | 0.183 | 0.197 | – | – | – | – |
0.147 C19 0.148 C23 | 0.092 | 0.099 | – | – |
| S4‐8 | 0.094 | 0.091 | 0.183 | 0.198 | – | – | – | – |
0.109 C20 0.108 C24 | 0.092 | 0.099 | – | – |
| S5‐1 | 0.116 | 0.087 | 0.194 | 0.202 | – | – | – | – |
0.144 C17 0.141 N23 | 0.100 | 0.102 | – | – |
| 2NS5‐2 | – | – | – | – |
0.169 S11 0.124 C17 | 0.162 | 0.244 | 0.206 | – | 0.029 | 0.031 | 0.129 | 0.107 |
| 2NS1‐6 | – | – | – | – |
0.118 C21 0.133 C23 | 0.155 | 0.225 | 0.193 | – | 0.027 | 0.036 | 0.116 | 0.098 |
| 2NS5‐3 | 0.125 | – | 0.187 | 0.141 | – | 0.160 | 0.240 | 0.201 | – | 0.069 | 0.061 | 0.159 | 0.131 |
| 2NS3‐6 | – | – | – | – |
0.122 C20 0.129 C22 | 0.153 | 0.222 | 0.190 | – | 0.028 | 0.028 | 0.115 | 0.096 |
| 2NS3‐7 | 0.058 | 0.034 | 0.083 | 0.067 |
0.078 C19 0.078 C23 | 0.156 | 0.226 | 0.191 | – | – | – | 0.127 | 0.110 |
| 5NS2‐6 | – | – | – | – |
0.131 C18 0.145 C22 | 0.159 | 0.227 | 0.184 | – | 0.051 | 0.012 | 0.115 | 0.092 |
| 5NS1‐1 | – | – | – | – |
0.143 C16 0.179 C23 | 0.156 | 0.221 | 0.197 | – | 0.049 | 0.011 | 0.114 | 0.101 |
| 5NS5‐4 | 0.070 | 0.083 | 0.107 | 0.134 | 0.099 O10 | 0.154 | 0.225 | 0.196 | – | 0.106 | 0.077 | 0.161 | 0.132 |
Values obtained from Reference [16].
Values obtained from Reference [15].
FIGURE 6Frontier molecular orbitals (HOMO and LUMO) for imidazole and nitroimidazole derivatives at the M06‐2X/6‐311+G(d,p) level of theory
Structural quality criteria
| ID | % Identity |
|
| % Coverage | Resolution | Score |
| Coenzyme | Ligand |
|---|---|---|---|---|---|---|---|---|---|
| 5GLG | 37.3 | 0.18 | 0.21 | 40 | 1.80 | 272 | 5.00E‐80 | FAD | Succinate |
| 1KSU | 35.4 | 0.17 | 0.24 | 39 | 2.00 | 239 | 1.00E‐67 | FAD | Fumarate |
| 1QJD | 35.2 | – | 0.27 | 39 | 1.80 | 238 | 5.00E‐67 | FAD | Malate |
| 1QO8 | 34.8 | 0.23 | 0.28 | 41 | 2.15 | 240 | 5.00E‐68 | FAD | – |
Method X‐ray diffraction (Values obtained from Reference [51]).
Method X‐ray diffraction (Values obtained from Reference [52]).
Method X‐ray diffraction (Values obtained from Reference [53]).
Method X‐ray diffraction (Values obtained from Reference [54]).
FIGURE 7Multiple sequence alignment for template and problem sequence. The residues that integrate the catalytic site of the FAD are in green box, and the residues that integrate the catalytic site of the fumarate are in yellow box
FIGURE 8Models generated for: (A) 1QJD (purple), (B) 1KSU (blue), (C) 5GLG (red), (D) 1QO8 (green). The values of the root mean square deviation (RMSD) were calculated with ProFit, , and the DOPE statistical score (discrete optimized protein energy) was calculated by MODELLER 9.21
FIGURE 9Selected models (magenta) and compared with their respective templates (blue): (A) 1QJD vs the model 2735, (B) 1KSU vs the model 5299, (C) 5GLG vs the model 4560, (D) 1QO8 vs the model 9109. The models were generated by MODELLER 9.21
FIGURE 10Ramachandran plots for the selected models: (A) model 2735 (1QJD), (B) model 5299 (1KSU), (C) model 4560 (5GLG), (D) model 9109 (1QO8)
FIGURE 11Molecular docking for: (A) The crystallized FAD‐1QJD (green) overlaid with NADH coupled to model 2735 (blue), (B) the crystallized FAD‐1KSU (green) overlaid with NADH coupled to model 5299 (red), (C) the crystallized FAD‐5GLG (green) overlaid with NADH coupled to model 4560 (yellow), and (D) the crystallized FAD‐1QO8 (green) overlaid with NADH coupled to model 9109 (magenta)
FIGURE 12Spatial location of the crystallized FAD (green) overlaid with FAD coupled to model 5299 (blue), the FAD coupled to 1KSU template (magenta), the NADH coupled to 1KSU template (yellow), and the NADH coupled to model 5299 (red)
FIGURE 13(A) Interactions of the FAD‐1KSU complex; (B) interactions of the NADH‐5299 complex. The green dotted lines illustrate the hydrogen bonds interactions, and red dotted lines display the hydrophobic interactions
FIGURE 14Crystal structure of 1KSU reveals no evidence of the presence of conserved water molecules within the ligand (fumarate, FUM)‐binding pocket
FIGURE 15Docking of water molecules to (A) FAD‐1KSU complex and to (B) FAD‐1KSU‐fumarate (FUM) complex (red spheres represent water molecules)
FIGURE 16Docking of water molecules to (A) NADH‐5299 complex and (B) NADH‐5299‐fumarate (FUM) complex (red spheres represent water molecules)
FIGURE 17Molecular docking of the NADH‐5299 complex with fumarate, selected ligands and reference molecules that conserve the catalytic site of the fumarate
Ligand interactions with the NADH‐5299 complex
| Ligands | Binding energy (kcal/mol) | Hydrophobic interactions | Hydrogen bonds |
|---|---|---|---|
|
|
|
|
|
| BNZ | −6.2 | Ala62, Arg89, Ile57, Thr483, Met63, Thr174, Tyr480, Tyr64, Phe479, NAD | Lys172 |
| M3 | −6.4 | Ala62, Leu85, Ile57, Arg89, Asp258, Lys172, Thr174, Phe479, Lys58, Met63, Tyr64, Ser61, NAD | |
| M35m | −6.0 | Ile57, Ala62, Leu85, Phe479, Met63, Tyr64, Asp258, Thr174, Arg89, Lys172, NAD | |
| M2 | −6.7 | Arg89, Lys172, Asp258, Thr174, Phe479, Met63, Tyr64, Ala62, Lys58, Ser61, Ile57, Leu85 | |
| M7D | −5.7 | Ser56, Lys58, Met63, Leu85, Ala62, Ser61, Thr483, Phe479 | Asn482 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| S2‐6 | −6.7 | Leu85, Ala62, Met63, Ser56, Phe479, Asn482, Ile57, Thr483, Lys58 | Arg89, Ser61 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| S4‐6 | −6.4 | Thr483, Asn482, Met63, Phe479, Ser56, Arg89, Leu85, Ile57, Lys58, Ala62 | Ser61 |
|
|
|
|
|
| 2NS5‐2 | −6.1 | Ser61, Thr483, Ser56, Phe479, Met63, Tyr64, Ala62, Leu85, Ile57 | Arg89, Lys58 |
|
|
|
|
|
| 2NS5‐3 | −5.8 | Phe479, Thr483, Ser56, Met63, Leu85, Ala62, Ser61 | Asn482 |
| 2NS3‐6 | −7.0 | Phe479, Lys58, Ile57, Arg89, Ala62, Leu85, Met63, Thr483 | Asn482, Ser56 |
| 2NS3‐7 | −7.3 | Phe479, Ser56, Lys58, Ile57, Met63, Ala62, Leu85, Arg89, Thr483 | Asn482 |
| 5NS2‐6 | −6.9 | Phe479, Lys58, Met63, Ile57, Ala62, Leu85, Arg89, Thr483 | Asn482, Ser56 |
|
|
|
| |
| 5NS5‐4 | −5.8 | Ser56, Phe479, Thr483, Ile57, Arg89, Leu85, Ala62 | Lys58 |